EGFR and HER3 are members of the human epidermal growth factor receptor (HER) family and are validated therapeutic targets in advanced solid tumors. EGFR overexpression drives tumor progression in ...

A new publication shines a spotlight on HER3, a long-overlooked member of the ErbB receptor family, revealing its critical role in cancer progression and resistance to therapy. Once considered a ...

Bladder cancer is the fifth most common cancer in men and ninth in women (Droller, 1998). Despite much research on the topic, it is still difficult to predict tumour progression, optimal therapy and ...

DALLAS - June 24, 2021 - Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, a new ...

Patritumab deruxtecan, with or without letrozole, showed similar efficacy to chemotherapy in high-risk HR-positive, HER2-negative breast cancer, with lower severe side effects. The SOLTI VALENTINE ...

“[...] we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC ...

The TUXEDO-3 trial is the first study to evaluate the intracranial and extracranial efficacy and safety of a novel anti-cancer drug in patients with breast or lung cancer and active brain metastases, ...

The buzz around HER3-targeting antibody-drug conjugates (ADCs) continues to grow. Only a week after BioNtech got in on the action, Endeavor BioMedicines has secured the rights to Hummingbird ...

BioNTech is flattering Daiichi Sankyo through imitation. Six months after picking up an Enhertu rival, the German biotech has paid $70 million upfront to MediLink Therapeutics for an antibody-drug ...

Please provide your email address to receive an email when new articles are posted on . In patients with non-small cell lung cancer (NSCLC), human epidermal growth factor receptor 3 (HER3) is ...